at Zacks.com (Nov 12, 2014)
Omeros (OMER) trades lower in the post-session after reporting that results from its first Phase 3 clinical trial evaluating OMS103HP in patients undergoing arthroscopic knee surgery did not meet endpoints. However, the drug developer said its plans for another study remain on track for the first half of next year. Shares -6.2% AH.
From other sites